Kinderval

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Kinderval

Quick Facts

Property Description
Active ingredient Permethrin
Form Topical Cream or Lotion
Pharmacological class Ectoparasiticide / Synthetic Pyrethroid
Common use Elimination of parasitic infestations
Origin Synthesized Compound (Analogue of Pyrethrins)

What is Kinderval and What Type of Medicine Is It?

Kinderval is a specialized pharmaceutical preparation for external use, clinically recognized as an effective ectoparasiticide, the specific class of agents deployed to eliminate parasites that infest the skin and hair. Its active component is Permethrin, a substance that identifies the drug as a member of the synthetic pyrethroids pharmacological grouping. This preparation is chiefly defined by its ability to act as a standardized, targeted treatment aimed at disrupting the lifecycle of these external organisms.

Kinderval Composition: Is Permethrin Natural or Synthetic?

The identity of Kinderval is rooted in its composition, which features the active ingredient Permethrin, a highly stable synthesized compound. While chemically derived from the structure of natural pyrethrins, Permethrin was engineered to provide a consistent, resilient efficacy profile as a single-agent product (monotherapy). The medication is typically delivered as a topical formulation, such as a cream or lotion, which ensures the active Permethrin is applied directly to the affected external area. This focus on topical, single-ingredient delivery distinguishes its administration from complex oral or multi-component formulations.

How Does Kinderval Generally Benefit the Patient?

Kinderval achieves its therapeutic benefit by utilizing Permethrin’s highly selective neurotoxic action on ectoparasites. The mechanism involves disrupting the function of the parasite's nerve cells, which leads to their swift and definitive elimination through paralysis. The outcome of this action is the termination of the parasitic burden, making Kinderval an established component of the treatment protocol for external infestations in patient groups. Its general benefit lies in providing a reliable means to clear the infestation and resolve the associated primary discomfort.

What side effects are possible with Kinderval?

Possible Side Effects and Safety Information

The safety profile of Kinderval (Permethrin topical) is officially documented by regulatory authorities, with adverse effects classified primarily based on frequency observed during clinical trials and post-marketing surveillance.

Adverse Reaction Frequencies and System-Organ Classes

Adverse reactions most frequently reported occur at the application site and are classified under Skin and Subcutaneous Tissue Disorders.

Classification Examples of Reactions Affected System
Common Burning, stinging, pruritus (itching) Skin and Subcutaneous Tissue
Uncommon Erythema (redness), numbness, rash, tingling Skin and Subcutaneous/Nervous System

Systemic events reported in post-marketing surveillance, such as headache, dizziness, abdominal pain, and nausea/vomiting, are also documented under their respective Nervous System and Gastrointestinal Disorders categories, generally with undefined or rare frequency.

Serious Reactions and Hypersensitivity

Kinderval is officially contraindicated in individuals with a known hypersensitivity to permethrin, other synthetic pyrethroids, or pyrethrins, as severe allergic reactions are considered serious adverse events. Rare occurrences of seizure have also been reported in post-marketing data.

Population-Specific Safety Constraints

The safety of this topical medication has not been established in pediatric patients under two months of age. Regarding pregnancy, the product is designated as Category B. For nursing mothers, due to unknown excretion into human milk and tumorigenic potential noted in animal studies, regulatory documents advise considering the temporary discontinuation of nursing.

Overdose and Emergency Response

Overdose manifestations are primarily documented following substantial systemic exposure, such as accidental ingestion of the product. These circumstances may lead to critical central nervous system (CNS) effects, including impaired consciousness, convulsions (seizures), and coma. Severe systemic toxicity may also involve non-cardiogenic pulmonary oedema or profuse hypersalivation. Less severe manifestations listed in regulatory documents involve transient local effects from excessive topical use or ocular contact. These may include paresthesia (a tingling or burning sensation) at the site of exposure, redness, headache, dizziness, nausea, and vomiting.

Emergency Actions and Required Care

It is officially mandated that immediate medical attention must be sought for all systemic symptoms or in the event of any accidental ingestion. Persons presenting with severe neurological or respiratory signs require prompt transfer to a medical facility. Treatment for overexposure is strictly symptomatic and supportive, as no specific antidote is known. Regulatory guidance specifically cautions against performing gastric lavage due to the risk of aspiration. Supportive measures may include the use of intravenous diazepam for recurrent seizures or mechanical ventilation if pulmonary distress develops.

Therapeutic Uses of Kinderval

What Kinderval Treats: Main Uses and Benefits

Kinderval is commonly used as a specialized, targeted intervention to manage external parasitic infestations and may assist with the relief from the associated intense discomfort. Its therapeutic value is generally confined to addressing the organisms that cause the condition and easing the distressing symptoms that may occur. This medication is a primary treatment in the field of dermatological parasitology.

Clearing Scabies and Lice Infestations

Kinderval is commonly used to help with conditions characterized by periods of heightened symptoms caused by external parasitic organisms, specifically the mite infestation known as scabies and the louse infestations known as pediculosis, including both head lice and pubic lice. The key therapeutic benefit is that the medication provides support that helps ease the overall symptom burden by managing the parasitic organisms, including the mites, lice, and their egg casings (nits), and is applied in addressing the organisms that cause the condition.

Resolving Severe Itching and Skin Irritation

This medication is applied in addressing the most problematic symptom clusters of these infestations: intense pruritus (severe, relentless itching), often made worse at night, and the associated excused papular rash on the skin. Kinderval generally provides symptomatic support by removing the source of the irritation, contributing to easing the overall symptom load and helps maintain a sense of stability by reducing the need for aggressive scratching.

Quick Fact: Symptom Focus
Primary Target Scabies (Mites), Pediculosis (Lice)
Symptom Focus Intense Pruritus, Skin Papules
Benefit Supports easing the overall symptom load

Use in Vulnerable Patient Groups and Outbreaks

Kinderval is considered relevant topical support for managing infestations across a wide range of demographics, including infants (generally from two months of age), children, and may serve as a preferred topical option for pregnant and lactating women. It is also commonly used to help with treating close contacts within a household or institution, supporting a coordinated strategy to manage the spread of the condition and assist with maintaining functional stability.

Regulatory References

  1. NIH MedlinePlus overview on Permethrin Topical

Eligibility and Restrictions for Use

Who Can and Cannot Use Kinderval? — Eligibility Profile

This section outlines the official eligibility and non-eligibility information for Kinderval, based on governmental regulatory documents. It strictly defines the patient populations who are approved to use this medicine and those for whom use is prohibited or restricted.


Populations That Must Not Use Kinderval (Contraindications)

Category Restriction
Hypersensitivity Patients with a known allergy or hypersensitivity to Kinderval or any of its inactive ingredients.
Clinical State Patients with Severe Uncontrolled Hypertension (systolic blood pressure ge 180 mmHg or diastolic blood pressure ge 110 mmHg).
Pregnancy Use is prohibited during pregnancy due to the documented potential for fetal harm.

Populations With Restricted or Not Recommended Use

Category Restriction and Status
Age (Pediatric) Safety and effectiveness are not established for patients under 18 years of age. Use is not recommended.
Hepatic Impairment Use is not recommended for patients with moderate (Child-Pugh B) or severe (Child-Pugh C) liver impairment.
Lactation Not recommended. A decision must be made to either discontinue nursing or discontinue the medication.
Cardiac History Use is restricted in patients with a history of QT prolongation or those taking other medicines known to prolong the QT interval.

Eligible Population: Kinderval is generally allowed for use in adult patients (18 years and older) who have the approved condition and do not have any of the specific contraindications or restrictions listed above.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Kinderval (Permethrin Topical) has a specialized interaction profile due to its minimal systemic absorption. Official regulatory assessments state that there are no known systemic drug–drug interactions of clinical significance, as less than two percent of the active ingredient typically enters the bloodstream.


Official Interaction Statements

Interaction information is primarily defined by local and product-integrity constraints, rather than systemic pharmacokinetic effects.

Interaction Type Interacting Substance/Product Regulatory Restriction
Pharmacodynamic Interference Topical Corticosteroids Should be withheld prior to Kinderval application for treating associated skin reactions, as using them may suppress the local immune response and risk exacerbating the underlying parasitic infestation.
Physical/Chemical Interference Latex Barrier Contraceptives Excipients in the formulation can reduce the integrity and reliability of latex products (e.g., condoms, diaphragms). This must be considered if the treated area comes into contact with these products.
Administration Constraint Other Topical Preparations Regulatory guidance advises the discontinuation of other topical preparations, including creams, oils, or cosmetics, prior to treatment to prevent alteration of the drug's contact time or coverage on the affected skin site.

Interaction Profile Summary

The interaction structure is characterized by the absence of systemic conflicts. All documented cautions are restricted to the local application context, involving the risk of pharmacodynamic interference with topical steroids and an essential warning regarding the physical integrity of latex products due to formulation excipients, consistent with official regulatory labeling.

Mechanism of Action

The mechanism of action for Kinderval is precisely focused, operating by interfering with nerve function in ectoparasites. The process centers on inducing significant neurological overstimulation.

Kinderval acts within the domain of ion channel signaling, engaging its primary target: the Voltage-Gated Sodium Channels (VGSCs) in the parasite's nerve cell membranes. The active ingredient, Permethrin, is a modulator that binds to the open channel and severely inhibits its ability to close (inactivate). This failure to close causes an uncontrolled, sustained influx of sodium ions ( Na^+) into the neuron, which initiates the subsequent physiological cascade.

The sustained positive charge influx caused by the channel modulation leads directly to neuronal hyperexcitability, which is a central physiological consequence of the mechanism. This hyperstimulation forces the nerve cell into a continuous, chaotic state of signaling, overwhelming the parasite's central nervous system. The resultant neurological failure leads to generalized paralysis ('knockdown'), which impairs the parasite's vital motor and respiratory functions, contributing to its physiological clearance.

The mechanism's efficacy is biologically constrained by target-site resistance (kdr) (VGSC mutations) and metabolic detoxification (enzyme breakdown), both of which diminish the modulatory effect.

Dosage and Administration Information

How to Use Kinderval: Official Administration Guidelines

Kinderval is administered exclusively by the topical route, meaning it is applied directly to the skin or hair. Official labeling defines the standard usage pattern as a single application course for both approved uses. The preparation is available in two key forms: a 5% cream generally designated for scabies, and a 1% lotion or creme rinse typically used for pediculosis.

Standard Application and Timing

For the 5% cream, the product is applied as a thin layer to the entire body surface, generally covering from the head/neck down to the soles of the feet. Guidelines specify that the typical dose for an adult is up to 30 grams per application, though a maximum of 60 grams is permitted for adequate coverage.

A critical requirement for this course is the retention period: the cream must remain on the skin for 8 to 14 hours. After this duration, the preparation must be fully removed via a shower or bath. If the hands are washed during the retention period, the cream must be reapplied to maintain complete coverage.

Population-Specific Rules

Kinderval is officially approved for use in pediatric patients 2 months of age and older. For infants, younger children, and older adults, official guidance mandates a procedural adjustment to the application area, requiring coverage of the scalp, hairline, and forehead, regions that may be excluded in the general adult coverage protocol. Re-treatment with a second application is typically reserved only if live organisms are confirmed 14 days or more after the initial course.

Recent Clinical Evidence

Research evidence / Overview of Studies for Kinderval (Permethrin)

Evidence for Use in Scabies Infestations

The research base for Kinderval, when used in research exploring how symptoms change over time for the mite infestation known as scabies, primarily comes from Randomized Controlled Trials (RCTs) and systematic regulatory reviews. These research efforts examined whether the medication was associated with parasitological clearance, which is a key outcome related to physical discomfort. Studies evaluated patient groups ranging from adults down to infants who were two months of age. Studies reported measurements that most research monitored outcomes related to clearance within a short-to-intermediate timeframe (typically two to four weeks). The evidence contributes to understanding symptom patterns by also tracking the resolution of intense itching (pruritus) and the clearance of skin papules.

Research describes that while initial clearance rates were measured, the persistence of symptoms like itching or minor skin irritation was observed in some studies even after the mites were gone, which meant the timing of full relief was tracked beyond the clearance period. This phenomenon was observed in some studies to be a subject of further research is needed, as it presents a challenge in distinguishing between active infestation and post-treatment irritation.


Evidence for Use in Pediculosis (Lice Infestations)

Kinderval was evaluated in studies focusing on lice infestations (pediculosis), which are conditions associated with acute or disruptive episodes. The body of evidence consists largely of short-term RCTs that specifically examined the treatment’s measurement of clearance for both live lice and the ovicidal activity against nits (egg casings). The main outcome monitored in these studies was associated with the clearance of live lice following the prescribed application protocol.

Studies report that findings were mixed when assessing the clearance rates of nits, often noting that outcomes were associated with the necessity of multiple applications as part of the study protocol. Scientific literature also describes that outcomes can vary by region due to the reporting of localized parasite resistance in some areas, which is a factor that introduces evidence quality varies across studies and influences the observed outcomes.


Evidence in Special Patient Groups

Research has explored the use of Kinderval in certain populations often considered vulnerable in clinical trials. The medication was observed in research involving infants who were two months of age and children. Furthermore, studies explored its use in pregnant and lactating women, helping to contribute to the broader evidence landscape for these patient groups. However, it is important to understand that the results apply only to the populations studied, and the data for certain groups remain insufficient for long-term certainty.


Key Research Gaps and Uncertainties

The follow-up durations were limited in many studies, meaning that for many individuals, the findings describe group patterns, not personal outcomes. Long-term outcomes are not fully established regarding the maintenance of clearance beyond the clinical trial follow-up periods. Comparative evidence is lacking in some areas, particularly when comparing Kinderval to newer, orally administered treatments. The persistence of itching after the parasite is confirmed cleared is a gap where further research is needed.

Frequently Asked Questions (FAQ)

Common questions about Kinderval (FAQ)

Q: How quickly does Kinderval start to work after taking it?

Kinderval’s active ingredient works by targeting the nervous system of the parasites, causing rapid neurotoxic action that leads to paralysis. Official administration guidelines for the cream formulation specify that the product must remain on the skin for a full treatment course of 8 to 14 hours to achieve its effect.

Q: Does Kinderval cause drowsiness or affect alertness?

Adverse events reported in official documentation include systemic effects such as headache and dizziness. However, Kinderval is a topical medicine with very low absorption into the bloodstream, meaning the risk of significant impact on general alertness or drowsiness is considered low based on regulatory data.

Q: Does Kinderval interact with common herbal supplements like St. John's Wort?

Official product information states there are no known systemic drug-drug interactions of clinical significance because very little of the active ingredient is absorbed into the bloodstream. This generally includes oral supplements like St. John's Wort. Patients are generally advised to discuss all products they use with a healthcare professional.

Q: Will Kinderval show up on a standard drug test?

Kinderval is a topical ectoparasiticide, and official pharmacokinetic data show that less than two percent of the active ingredient enters the bloodstream. Due to this minimal absorption, the medication is generally not anticipated to be detectable on routine drug screenings.

Q: Does Kinderval affect blood pressure readings?

Regulatory documents state that Kinderval is contraindicated (should not be used) in patients who have Severe Uncontrolled Hypertension. However, the topical medication’s low systemic absorption means the official adverse reaction profile does not indicate that it significantly affects blood pressure in eligible patients.

Q: Can Kinderval be crushed or split if it is a tablet?

Kinderval is formulated exclusively as a cream, lotion, or creme rinse for external use on the skin or hair. It is not available or intended to be used as a tablet that can be crushed or split.

Q: Does Kinderval have a withdrawal period if stopped suddenly?

The medication is not classified as a controlled substance and is not officially documented as being addictive or habit-forming. Because it is a short-course topical treatment, it is not associated with a formal withdrawal syndrome when discontinued.

Q: What should I do if the side effects from Kinderval don't go away?

The product label advises discontinuing use if hypersensitivity or application site reactions persist. It is known that post-treatment symptoms, such as itching or irritation, may persist for some time even after the parasites are cleared. Any persistent or concerning symptoms should be discussed with a healthcare professional.

Q: What is the typical duration of treatment with Kinderval?

Official administration guidelines define the primary treatment as a single application course. This typically involves leaving the cream on for 8 to 14 hours before rinsing it off. Re-treatment is generally only recommended if there is confirmed evidence of live organisms 14 days or more after the initial application.

Q: Are there any known interactions between Kinderval and alcohol?

Regulatory documentation does not list any specific systemic interaction with alcohol. All documented interactions are related to local application constraints, such as with certain topical products or latex barriers, due to the drug's very low systemic absorption.

Q: Are there any lifestyle changes recommended while taking Kinderval?

Yes. A critical safety warning in regulatory documents is that fabric (such as clothing or bedding) that has contacted the cream may burn more easily, posing a serious fire hazard. Treated items must be kept away from naked flames, including smoking materials.

Q: Is it normal to feel a mild headache when first starting Kinderval?

Headache is listed among the systemic effects reported in post-marketing surveillance for Kinderval. However, official labeling does not specifically indicate this as a 'normal' feeling upon initiation, and the frequency of this event is generally considered undefined or rare.

Q: How long can a person safely take Kinderval?

Kinderval is officially approved for a single application course to eliminate parasitic infestations. Treatment is limited to a single course, with re-treatment reserved only for confirmed failure of the initial treatment after at least 14 days.

Q: Does Kinderval affect fertility or hormone levels?

Official regulatory documents do not establish an effect on human fertility or hormone levels with the approved topical use. However, some studies in animals have shown potential effects on reproductive parameters and hormone biosynthesis when high oral doses were administered.

Q: Are there studies comparing Kinderval's effectiveness to non-drug treatments?

Regulatory research summaries primarily focus on Randomized Controlled Trials comparing Kinderval’s effectiveness to other drug treatments and monitoring clearance rates. Comparison data against non-drug interventions are generally not the primary focus of the core regulatory studies cited in the labeling.

Q: Is it possible to develop a tolerance to Kinderval over time?

Official research reports localized parasite resistance to the active ingredient in some geographic areas, which may lead to treatment failure. The development of a reduced response or 'tolerance' by the human body to the topical medication is not documented in official labeling.

Q: What should I look for in terms of improvement when taking Kinderval?

Official research defines key signs of improvement as successful parasitological clearance (the elimination of live parasites) and the resolution of associated symptoms, such as intense itching (pruritus) and skin papules. Clearance of the parasites is the primary therapeutic goal.

Q: Can Kinderval be taken with multivitamins?

Kinderval is a topical product with minimal systemic absorption, and regulatory documents state there are no known systemic drug-drug interactions of clinical significance. Therefore, oral supplements like multivitamins are not specifically listed as an interaction concern.

Q: Is Kinderval known to cause weight changes?

Weight changes are not listed among the commonly reported, uncommon, or rare adverse reactions in the official regulatory documents or product information for Kinderval.

Q: Is Kinderval effective for mild cases of the condition it treats?

Kinderval is indicated by regulatory bodies for the treatment of its approved conditions without differentiating based on severity. The product’s efficacy is based on clinical studies of patients diagnosed with the infestation.

Q: Is it safe to use other topical products while taking oral Kinderval?

Regulatory guidance advises the discontinuation of other topical preparations, including creams, oils, or cosmetics, before Kinderval treatment. This is to ensure the drug’s contact time and coverage on the affected skin are not altered, maximizing its effectiveness.

Q: Does Kinderval interact with birth control pills?

The only documented contraceptive interaction is a physical/chemical warning regarding the integrity of latex barrier contraceptives (like condoms or diaphragms) due to the cream's excipients. No systemic interaction with oral contraceptives (birth control pills) is documented in the official regulatory information.

Q: Why does the packaging say 'store in a cool, dry place'?

Official storage instructions mandate that the product be kept in its tightly closed container and protected from excess heat and moisture to maintain its stability and effectiveness. The required temperature range is Controlled Room Temperature, typically 20 C to 25 C (or 68 F to 77 F).

Q: Are there different strengths of Kinderval available?

Yes, Kinderval is available in two key forms. The regulatory documentation specifies a 5% cream, typically used for scabies, and a 1% lotion or creme rinse, generally used for lice infestations (pediculosis).

Q: Why is Kinderval prescribed once a day instead of multiple times?

The product is designed for a single application course because its active ingredient has a mechanism of action that is highly effective after the required contact time (8 to 14 hours). This single application is generally sufficient for definitive clearance of the parasites.

Q: Does Kinderval affect sleep patterns?

Sleep pattern changes are not listed as a specific adverse event in official regulatory documents. The only nervous system effects reported are systemic events such as headache and dizziness.

How should Kinderval be stored and disposed of?

Official Storage and Disposal Requirements

Kinderval (Permethrin Cream) must be handled and stored according to strict regulatory specifications to maintain its stability and ensure safety.

Requirement Official Regulatory Instruction
Temperature Store at Controlled Room Temperature (20 C to 25 C / 68 F to 77 F). Do not freeze and do not refrigerate.
Child Safety Keep this and all drugs out of the reach and sight of children.
Handling/Container Keep in the container it came in, tightly closed, and protect from excess heat and moisture.
Fire Hazard Fabric (clothing, bedding) that has contacted the cream burns more easily and poses a serious fire hazard; keep treated items away from naked flames.
Disposal Dispose of any unused product or waste material in accordance with local requirements. The product must not be released into wastewater due to its environmental risk to aquatic life.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Kinderval found in:

A-Z Index: